IDEAYA Biosciences Secures Clearance for IDE034
ByAinvest
Monday, Dec 1, 2025 11:32 am ET1min read
IDYA--
Ideaya Biosciences has announced clearance for IDE034, a precision medicine oncology company developing targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (IDE196), IDE397, IDE161, and GSK101. IDE196 is a PKC inhibitor being evaluated as a synthetic lethal combination therapy, while IDE397 is a MAT2A inhibitor for solid tumors with MTAP deletions. IDE161 is a PARG inhibitor for tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet